

**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.


**Sample ID :**



001136021

Test Description	Value(s)	Reference Range	
<b><u>COMPLETE BLOOD COUNT ( CBC )</u></b>			
ESR	<b>70</b>	13.5 - 18.0	mm/hr
Hemoglobin (Hb)	<b>13.3</b>	13.5 - 18.0	gm/dL
Erythrocyte (RBC) Count	<b>4.43</b>	4.7 - 6.0	mil/cu.mm
Packed Cell Volume (PCV)	<b>38.0</b>	42 - 52	%
Mean Cell Volume (MCV)	85.78	78 - 100	fL
Mean Cell Haemoglobin (MCH)	30.02	27 - 31	pg
Mean Corpuscular Hb Concn. (MCHC)	35	32 - 36	g/dL
Red Cell Distribution Width (RDW)	11.5	11.5 - 14.0	%
Total Leucocytes (WBC) Count	5800	4000-10000	cell/cu.mm
Neutrophils	63	40 - 80	%
Lymphocytes	27	20 - 40	%
Monocytes	9	2 - 10	%
Eosinophils	1	1 - 6	%
Basophils	<b>0</b>	1-2	%
Absolute Neutrophil Count	3654	2000 - 7000	/c.mm
Absolute Lymphocyte Count	1566	1000 - 3000	/c.mm
Absolute Monocyte Count	522	200 - 1000	/c.mm
Absolute Eosinophil Count	58	20 - 500	/c.mm
Absolute Basophils Count	<b>0</b>	20 - 100	/c.mm
Platelet Count	253	150 - 450	10 <sup>3</sup> /ul
Mean Platelet Volume (MPV)	9.3	7.2 - 11.7	fL
PCT	0.24	0.2 - 0.5	%
PDW	9.2	9.0 - 17.0	%

**\*\*END OF REPORT\*\***



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**



001136021

Test Description	Value(s)	Reference Range
------------------	----------	-----------------

**URINE COMPLETE ANALYSIS,**

**Physical Examination**

Quantity	32	-	ml
Colour	Pale Yellow	Pale yellow/Yellow	
Appearance	Clear	Clear	
Specific Gravity	1.015	1.005-1.025	
pH	6.0	5.0 - 8.0	
Deposit	<b>Present</b>	Absent	

**Chemical Examination**

Protein	Absent	Absent
Sugar	<b>Present (+++)</b>	Absent
Ketones	Absent	Absent
Bile Salt	Absent	Absent
Bile Pigment	Absent	Absent
Urobilinogen	Normal	Normal

**Microscopic Examination (/hpf)**

Pus Cell	2-4	Upto 5
Epithelial Cells	1-2	Upto 5
Red Blood Cells	Absent	Absent
Casts	Absent	Absent
Crystals	Absent	Absent
Amorphous Deposit	Absent	Absent
Yeast Cells	Absent	Absent
Bacteria	Absent	Absent
Other findings	Not seen	Not seen



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**




001136021

---

Test Description	Value(s)	Reference Range
------------------	----------	-----------------

---

\*\*END OF REPORT\*\*



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**



001136021

Test Description	Value(s)	Reference Range
<b><u>STOOL ROUTINE ANALYSIS</u></b>		
Color	Brownish	Brown
Consistency	Semisolid	Solid - Semi solid
Reaction (pH)	Acidic	Acidic - Alkaline
Method : Methyl Red & Bromothymol Blue		
Mucous	Absent	Absent
Blood	Absent	Absent
Pus cells	2-3/hpf	Few /hpf
Epithelial cells	1-2/hpf	-- /hpf
RBC	Absent	Absent /hpf
Ova	Not found	Absent /hpf
Cyst	Not found	Absent /hpf
Starch granules	Absent	None to small amount /hpf
Vegetable cells	Absent	-- /hpf
Fat globules	Absent	Absent /hpf
Others	Nil	/hpf
Method : Microscopy (Concentration technique)		

**\*\*END OF REPORT\*\***



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**



001136021

Test Description	Value(s)	Reference Range
<b><u>BLOOD GROUP &amp; RH TYPING</u></b>		
Blood Group (ABO typing) Method : Manual-Hemagglutination	"B"	
RhD Factor (Rh Typing) Method : Manual hemagglutination	Positive	

\*\*END OF REPORT\*\*



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**



001136021

Test Description	Value(s)	Reference Range
------------------	----------	-----------------

**Glycosylated HbA1c**

<b>HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD</b>	<b>12.7</b>	<b>%</b>
Method : (HPLC, NGSP certified)		
Estimated Average Glucose :	317.79	- mg/dL

**Interpretation**

As per American Diabetes Association (ADA)	
Reference Group	HbA1c in %
Non diabetic adults >=18 years	<5.7
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
Therapeutic goals for glycemic control	Age > 19 years Goal of therapy: < 7.0 Action suggested: > 8.0 Age < 19 years Goal of therapy: <7.5

**Note:**

1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled .
2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

**Comments**

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**



001136021

---

Test Description	Value(s)	Reference Range
------------------	----------	-----------------


---

**ADA criteria for correlation between HbA1c & Mean plasma glucose levels.**

HbA1c(%)	Mean Plasma Glucose (mg/dL)
6	126
7	154
8	183
9	212
10	240
11	269
12	298

---

**\*\*END OF REPORT\*\***



DR.UMA SAROJINI .K MBBS.,DCP.,

**Scan to Validate**



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**



001136021

Test Description	Value(s)	Reference Range
------------------	----------	-----------------

### THYROID PROFILE TEST - TOTAL


T3-Total	88.97	60 - 200	ng/dL
T4-Total	9.80	4.52 - 12	ug/dL
TSH-Ultrasensitive	3.02	0.32 - 5.5	uIU/mL

Method : CLIA

### **Interpretation**

TSH	T3	T4	Suggested Interpretation for the Thyroid Function Tests Pattern
Raised	Within range	Within range	Raised Within Range Within Range .Isolated High TSH especially in the range of 4.7 to 15 mIU/ml is commonly associated with Physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism. Intermittent 14 therapy for hypothyroidism .Recovery phase after Non-Thyroidal illness"
Raised	Decreased	Decreased	Chronic Autoimmune Thyroiditis Post thyroidectomy, Post radioiodine Hypothyroid phase of transient thyroiditis"
Raised or within range	Raised	Raised or within range	Interfering antibodies to thyroid hormones (anti-TPO antibodies) Intermittent 14 therapy or T4 overdose •Drug interference- Amiodarone, Heparin, Beta blockers, steroids, anti-epileptics.
Decreased	Raised or within range	Raised or within range	Isolated Low TSH -especially in the range of 0.1 to 0.4 often seen in elderly & Range Range associated with Non-Thyroidal illness .Subclinical Hyperthyroidism .Thyroxine ingestion'
Decreased	Decreased	Decreased	Central Hypothyroidism .Non-Thyroidal illness .Recent treatment for Hyperthyroidism (TSH remains suppressed)"
Decreased	Raised	Raised	Primary Hyperthyroidism (Graves' disease). Multinodular goitre, Toxic nodule •Transient thyroiditis: Postpartum, Silent (lymphocytic), Postviral (granulomatous, subacute, DeQuervain's), Gestational thyrotoxicosis with hyperemesis gravidarum"
Decreased Within Rang	Raised	Within range	T3 toxicosis •Non-Thyroidal illness
Within range	Decreased	Within range	Isolated Low T3-often seen in elderly & associated Non-Thyroidal illness In elderly the drop in T3 level can be upto 25%.

**\*\*END OF REPORT\*\***



DR.UMA SAROJINI .K MBBS., DCP.,

**Scan to Validate**





**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**




001136021

Test Description	Value(s)	Reference Range	
<b><u>LIPID PROFILE</u></b>			
Cholesterol-Total Method : Spectrophotometry	<b>204</b>	Desirable level   < 200 Borderline High   200-239 High   >or = 240	mg/dL
Triglycerides Method : Serum, Enzymatic, endpoint	85	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
HDL Cholesterol Method : Serum, Direct measure-PEG	55	Normal: > 40 Major Risk for Heart: < 40	mg/dL
LDL Cholesterol Method : Enzymatic selective protection	132	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190	mg/dL
VLDL Cholesterol Method : Serum, Enzymatic	17	6 - 38	mg/dL
CHOL/HDL Ratio Method : Serum, Enzymatic	3.71	3.5 - 5.0	
LDL/HDL Ratio Method : Serum, Enzymatic	<b>2.40</b>	2.5 - 3.5	

**Note:**

8-10 hours fasting sample is required.

**\*\*END OF REPORT\*\***



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**




001136021

Test Description	Value(s)	Reference Range	
<b><u>RENAL PROFILE</u></b>			
Urea Method : Uricase	31	19-42	mg/dL
Blood Urea Nitrogen-BUN Method : Serum, Urease	14.47	9-20	mg/dL
Creatinine Method : Serum, Jaffe	0.8	0.66-1.25	mg/dL
Uric Acid Method : Serum, Uricase	5.7	3.5-8.5	mg/dL

**Remark:**

In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by multiplying by 2.14.

**\*\*END OF REPORT\*\***



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**



001136021

Test Description	Value(s)	Reference Range	
<b><u>LIVER FUNCTION TEST</u></b>			
Total Protein Method : Serum, Biuret, reagent blank end point	7.1	6.3-8.2	g/dL
Albumin Method : Serum, Bromocresol green	4.1	3.5-5.0	g/dL
Globulin Method : Serum, EIA	3	1.8 - 3.6	g/dL
A/G Ratio Method : Serum, EIA	1.37	1.2 - 2.2	
Bilirubin - Total Method : Serum, Jendrassik Grof	0.5	0.3-1.2	mg/dL
Bilirubin - Direct Method : Serum, Diazotization	0.2	< 0.2	mg/dL
Bilirubin - Indirect Method : Serum, Calculated	0.3	0.1 - 1.0	mg/dL
SGOT Method : Serum, UV with P5P, IFCC 37 degree	21	17-59	U/L
SGPT Method : Serum, UV with P5P, IFCC 37 degree	23	21-72	U/L
Alkaline Phosphatase Method : PNPP-AMP Buffer/Kinetic	116	30 - 120	U/L
GGT-Gamma Glutamyl Transpeptidase Method : Serum, G-glutamyl-carboxy-nitroanilide	40	< 55	U/L

**\*\*END OF REPORT\*\***



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**



001136021

Test Description	Value(s)	Reference Range
------------------	----------	-----------------

**PSA-Total (Prostate-specific antigen-Total)**

**PSA Profile \***

PSA (Prostate Specific Antigen)-Total                      0.66                      0 - 4.0                      ng/mL

Method : Serum, CLIA

**Interpretation:**

1. Increased levels are noted in Prostate cancer, Benign prostatic hypertrophy, Prostatitis

PSA (Prostate-Specificantigen)-Free \*                      -                      0.0 - 0.5                      ng/mL

Method : Serum, CLIA

**Interpretation & Remarks:**

- Normal results do not eliminate the possibility of prostate cancer.
- Values obtained with different assay methods or kits may be different and cannot be used interchangeably.
- Tumor markers are not specific for malignancy. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease
- Specimens drawn from patients undergoing prostate manipulation, especially needle biopsy and transurethral resection, may show erroneously high prostatic-specific antigen (PSA) results. Care should be taken that specimens are drawn before these procedures are performed.
- The percentage of free PSA can be used to estimate how likely it is that a biopsy will show cancer.
- If the percentage of free PSA is higher than 25%, the likelihood of prostate cancer is about 8%.
- If the percentage of free PSA is less than 10%, then the likelihood of prostate cancer rises to 56%.

Free PSA / Total PSA %                      -                      -

Method : Serum

**Interpretation**

- When total prostate-specific antigen (PSA) concentration is <2.0 ng/mL, the probability of prostate cancer in asymptomatic men is low, further testing and free PSA may provide little additional information. When total PSA concentration is >10.0 ng/mL, the probability of cancer is high and prostate biopsy is generally recommended.
- The total PSA range of 4.0 to 10.0 ng/mL has been described as a diagnostic "gray zone," in which the free:total PSA ratio helps to determine the relative risk of prostate cancer (see table below). Therefore, some urologists recommend using the free:total ratio to help select which men should undergo biopsy. However even a negative result of prostate biopsy does not



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**



001136021

Test Description	Value(s)	Reference Range
------------------	----------	-----------------

rule-out prostate cancer. Up to 20% of men with negative biopsy results have subsequently been found to have cancer.

Based on free:total PSA ratio: the percent probability of finding prostate cancer on a needle biopsy by age in years:

Free:total PSA ratio	50-59 years	60-69 years	> or =70 years
< or =0.10	49.2%	57.5%	64.5%
0.11-0.18	26.9%	33.9%	40.8%
0.19-0.25	18.3%	23.9%	29.7%
>0.25	9.1%	12.2%	15.8%


**Cautions**

- Normal results do not eliminate the possibility of prostate cancer.
- Values obtained with different assay methods or kits may be different and cannot be used interchangeably
- Tumor markers are not specific for malignancy. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

**Interfering factors :**

- Prostatic massage
- Proctoscopy
- Prostatic biopsy
- Prostate cancer patients receiving treatment with antiandrogens and luteinizing hormone-releasing factor agonists may exhibit markedly decreased levels of PSA. Also, men treated for benign prostatic hyperplasia with inhibitors of 5-alpha-reductase (finasteride) may demonstrate a significant reduction in PSA levels compared to values before treatment. Care should be taken in interpreting values for these individuals.
- In patients receiving therapy with high biotin doses (ie, >5 mg/day), no sample should be taken until at least 8 hours after the last biotin administration.

**\*\*END OF REPORT\*\***



DR.UMA SAROJINI .K MBBS.,DCP.,

**Scan to Validate**



Obli Towers, 594, D.B. Road, R. S. Puram, Coimbatore-641 002. Mobile : 99430 99994 email: info@arthiscans.com

**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.

**Sample ID :**



001136021

Test Description	Value(s)	Reference Range
<b><u>GLUCOSE (F)</u></b>		
Glucose fasting Method : GOD-POD	<b>338</b>	Normal: 70 - 120 mg/dL

**\*\*END OF REPORT\*\***



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate



**Patient Name :** MR. JANARTHANAM R

**Age / Gender :** 52 years / Male

**Patient ID :** 74748

**Referral :** MediWheel

**Collection Time :** Dec 26, 2021, 08:24 a.m.

**Reporting Time :** Dec 26, 2021, 04:06 p.m.


**Sample ID :**



001136021

Test Description	Value(s)	Reference Range
<b><u>GLUCOSE (PP)</u></b>		
Blood Glucose-Post Prandial Method : GOD-POD	415	80 - 140 mg/dL

\*\*END OF REPORT\*\*



DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

